A Legacy of Power and Turbulence

Alan Greenspan, the legendary economist who served as the chairman of the Federal Reserve for nearly two decades, has passed away at the age of 100. His death was confirmed on Monday by his wife, renowned NBC News correspondent Andrea Mitchell.

Mitchell, who was married to Greenspan for 29 years, shared a poignant statement confirming that he died at their home due to complications from Parkinson’s disease. “He was a giant of a man who helped shape the U.S. economy for decades under presidents of both parties, but was always honest in acknowledging his mistakes,” Mitchell said.

Serving five terms as the Fed chair under four different presidents—Ronald Reagan, George H.W. Bush, Bill Clinton, and George W. Bush—Greenspan’s influence on the global financial landscape was unparalleled. Often referred to as “The Maestro,” he was widely credited with overseeing one of the most prosperous periods in American history, including the longest economic expansion from 1991 to 2001.

Born on March 6, 1926, in New York City, Greenspan’s journey began with a passion for music. A graduate of the Juilliard School, he spent time as a professional jazz musician before pivoting to economics at New York University. His early association with philosopher Ayn Rand profoundly shaped his views on laissez-faire capitalism, a philosophy that would later influence his tenure as a policymaker.

Navigating Modern Capitalism

Greenspan took the helm of the Fed in 1987, shortly before the infamous “Black Monday” market crash. His swift, decisive actions to provide liquidity to the markets during that crisis helped cement his reputation as a steady hand. Throughout the 90s and early 2000s, his ability to manage interest rates became legendary, with investors and politicians alike watching his every word to forecast market moves.

However, his legacy is not without significant controversy. Critics often point to his advocacy for financial deregulation as a contributing factor to the 2008 global financial crisis. Greenspan himself later acknowledged the complexity of the economic landscape, referring to the crisis as a “once-in-a-century credit tsunami.”

Despite these challenges, he remained a fixture of American public life, advising presidents and maintaining a unique reputation as the world’s most powerful central banker. Beyond the boardroom, he was a man of varied interests, ranging from his love for the Washington Commanders to his deep appreciation for jazz music.

“To me he was my husband, who shaped my life from our very first date in 1984,” Mitchell added. “He will be remembered for his brilliance and his kindness. Being his life partner was the joy of my life.”

As the world reflects on his century-long life, the financial community remembers a man who defined the American economy for a generation.

The Background of the Conflict

In a major legal development that has sent ripples through the American judiciary, the U.S. Supreme Court has officially declined to hear an appeal from 98-year-old federal judge Pauline Newman. The decision, handed down this Monday, leaves in place a multi-year suspension that has barred one of the nation’s most storied jurists from hearing cases since 2023.

Judge Pauline Newman, a Reagan appointee who has served on the U.S. Court of Appeals for the Federal Circuit since 1984, is widely recognized for her expertise in patent law and her prolific dissent-writing, earning her the nickname the “Great Dissenter.”

The controversy began in the spring of 2023, when Chief Judge Kimberly Moore and other colleagues on the Federal Circuit raised concerns regarding Judge Newman’s mental fitness. They cited reports from court staff describing the judge’s demeanor as “paranoid,” “agitated,” and “bizarre.” Following these allegations, the court’s leadership moved to initiate misconduct procedures under the Judicial Conduct and Disability Act.

Constitutional Arguments and Judicial Independence

When requested to undergo court-ordered medical examinations, Judge Newman refused, citing her own independent medical evaluations that she argued proved her fitness. Her subsequent suspension—which has now lasted nearly three years—became the subject of a fierce legal battle.

Newman’s legal team, represented by the New Civil Liberties Alliance, argued that the suspension was not only unconstitutional but a dangerous overreach. They contended that federal judges are granted lifetime tenure by the Constitution and can only be removed via the formal impeachment process in Congress.

“It is a dark day for the independence of the federal judiciary,” said Mark Chenoweth, President of the NCLA. “The cert denial in this case means that Judge Newman’s due process and other complaints… never have and never will receive a merits decision from an Article III court.”

Why the Supreme Court Stayed Out

The Justice Department, representing the Federal Circuit judges, successfully urged the Supreme Court to dismiss the appeal. They argued that the lower courts were correct in their findings that the federal judiciary possesses the authority to police itself, particularly regarding allegations of misconduct or incapacity. Previous rulings by the D.C. Circuit Court of Appeals had already held that existing law prevents courts from intervening in these types of internal administrative actions.

For now, the legal door remains shut. Judge Newman continues to hold her office, but she remains indefinitely sidelined from the bench—a situation many legal scholars view as a “stealth impeachment” that circumvents the standard constitutional checks and balances.

What’s Next?

While the Supreme Court’s decision is a definitive blow to Newman’s immediate goal of reinstatement, the debate surrounding judicial independence is far from over. As the oldest federal judge in U.S. history, Newman’s case serves as a litmus test for how the American legal system handles the intersection of aging, mental fitness, and the protection of lifetime tenure.

A New “Pre-Issuance” Hurdle

The landscape of American scientific research is facing a seismic shift. A new proposal from the Office of Management and Budget (OMB) aims to fundamentally rewrite the rules for how federal agencies—including the National Institutes of Health (NIH)—award and manage research grants.

This latest move is designed to implement President Trump’s 2025 executive order, which seeks to tighten political control over the billions of taxpayer dollars that fuel medical and scientific advancement in the United States.

Under the proposed framework, the traditional peer-review process—long considered the “gold standard” for scientific objectivity—would be relegated to an advisory role. Instead, the final say on grant funding would rest with political appointees.

These officials are required to conduct a “pre-issuance review” for all discretionary awards. The goal, according to the administration, is to ensure that every project explicitly advances the President’s policy priorities. If a grant is deemed inconsistent with agency goals or the broader “national interest,” the administration would have the authority to block or even terminate the funding mid-project.

Impact on DEI and Research Priorities

The proposal explicitly targets specific areas of study. It outlines strict criteria for withholding federal dollars from initiatives related to:

• Diversity, Equity, and Inclusion (DEI): Policies or programs that prioritize these values are effectively barred from federal funding.
• Gender Ideology: The rule specifically prohibits funding for work that denies the “biological reality of sex” or supports gender transition procedures for individuals under the age of 19.

“What OMB is proposing is not a reform of grants management,” argued Elizabeth Ginexi, a former NIH program official. “It is a complete political control apparatus layered over every stage of the federal science funding lifecycle.”

Why the White House Says It’s Necessary

The administration maintains that these changes are about accountability. Officials argue that past grantmaking processes lacked transparency, allowing taxpayer resources to be funneled into “woke” programs that do not serve the core missions of federal agencies. By centralizing oversight, the White House claims it is protecting the public purse and ensuring that science remains aligned with the law and current government policy.

The Scientific Community’s Reaction

The proposal has triggered alarm bells across the academic and medical communities. Groups like Stand Up for Science have decried the move as an “unprecedented power grab” by OMB Director Russell Vought.

Critics warn that these rules will:

1. Stifle Innovation: By prioritizing political alignment over scientific merit, the U.S. risks falling behind in global research and development.
2. Drive Away Talent: Many researchers fear that a politicized environment will lead to a “brain drain,” where top scientists choose to work in the private sector or abroad.

1. Create Massive Uncertainty: With the power to terminate ongoing projects, the administration has created an environment where long-term medical studies are no longer guaranteed the stable funding they require to reach breakthroughs.

What’s Next?

The future of U.S. research funding hangs in the balance. The administration is currently accepting public comments on the proposal through July 13. Once the comment period closes, the OMB and federal agencies will determine whether to move forward with the rules as written or implement revisions.

For many researchers, the stakes couldn’t be higher. In an era where scientific discovery is the backbone of national health and prosperity, the question remains: Can American science remain independent when the strings are held by political appointees?